Back to results
US 2019/0290764 A1Published application
Saposin c pharmaceutical compositions and methods of treating cancer
AssigneeBexion Pharmaceuticals Inc.
InventorsEllen K. Monson, Xiaochen Wei, Ray Takigiku, Charles A. Cruze, III, Joseph W. Wyse
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.
Claims41
A composition comprising:
- a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 with zero to four amino acid insertions, substitutions, or deletions;
- a phosphatidylserine lipid;
- a buffer at pH 5.0 to 8.0;
- trehalose at 1.5 to 9 percent w/w;
- t-butyl alcohol at 0 to 35 percent;
- and
- water,
- wherein the polypeptide is at a concentration of 0.4 to 5.0 mg/ml, and the molar ratio of the phosphatidylserine lipid to the polypeptide is in the range of 8:1 to 20:1.
6 more elements
A composition in solid form comprising:
- a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 with zero to four amino acid insertions, substitutions, or deletions;
- a phosphatidylserine lipid;
- a buffer;
- and
- trehalose at 75 to 90 percent w/w,
- wherein the polypeptide is at a concentration of 3.2 to 4.4 percent w/w, and the molar ratio of phosphatidylserine lipid to polypeptide is in the range of 8:1 to 20:1.
4 more elements
A pharmaceutical composition comprising:
- a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 with zero to four amino acid insertions, substitutions, or deletions;
- a phosphatidylserine lipid;
- a buffer at pH 5.0 to 8;
- trehalose at 1.5 to 9 percent w/v;
- and
- water,
- wherein the polypeptide is at a concentration of 0.4 to 5 mg/ml, and the molar ratio of phosphatidylserine lipid to polypeptide is in the range of 8:1 to 20:1.
5 more elements
Dependencies are inferred from the claim text.